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Abstract
Background: Heart ischemia can rapidly induce apoptosis and mitochondrial dysfunction via mitochondrial
permeability transition-induced cytochrome c release. We tested whether nitric oxide (NO) can block this
damage in isolated rat heart, and, if so, by what mechanisms.
Methods: Hearts were perfused with 50 μM DETA/NO (NO donor), then subjected to 30 min stop-flow
ischemia or ischemia/reperfusion. Isolated heart mitochondria were used to measure the rate of mitochondrial
oxygen consumption and membrane potential using oxygen and tetraphenylphosphonium-selective electrodes.
Mitochondrial and cytosolic cytochrome c levels were measured spectrophotometrically and by ELISA. The
calcium retention capacity of isolated mitochondria was measured using the fluorescent dye Calcium Green-5N.
Apoptosis and necrosis were evaluated by measuring the activity of caspase-3 in cytosolic extracts and the activity
of lactate dehydrogenase in perfusate, respectively.
Results: 30 min ischemia caused release of mitochondrial cytochrome c to the cytoplasm, inhibition of the
mitochondrial respiratory chain, and stimulation of mitochondrial proton permeability. 3 min perfusion with 50
μM DETA/NO of hearts prior to ischemia decreased this mitochondrial damage. The DETA/NO-induced
blockage of mitochondrial cytochrome c release was reversed by a protein kinase G (PKG) inhibitor KT5823, or
soluble guanylate cyclase inhibitor ODQ or protein kinase C inhibitors (Ro 32-0432 and Ro 31-8220). Ischemia
also stimulated caspase-3-like activity, and this was substantially reduced by pre-perfusion with DETA/NO.
Reperfusion after 30 min of ischemia caused no further caspase activation, but was accompanied by necrosis,
which was completely prevented by DETA/NO, and this protection was blocked by the PKG inhibitor. Incubation
of isolated heart mitochondria with activated PKG blocked calcium-induced mitochondrial permeability transition
and cytochrome c release. Perfusion of non-ischemic heart with DETA/NO also made the subsequently isolated
mitochondria resistant to calcium-induced permeabilisation, and this protection was blocked by the PKG
inhibitor.
Conclusion: The results indicate that NO rapidly protects the ischemic heart from apoptosis and mitochondrial
dysfunction via PKG-mediated blockage of mitochondrial permeability transition and cytochrome c release.
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Endogenous or exogenous nitric oxide (NO) can protect
the heart from ischemia plus reperfusion-induced dam-
age, but the mechanisms of this protection are not entirely
clear [1,2]. Suggested mechanisms include: improving
coronary vascular perfusion, decreasing monocyte infil-
tration, improving contractile function, opening of mito-
chondrial K+ATP channels, inhibition of mitochondrial
respiration, inhibition of mitochondrial permeability
transition or inhibition of apoptosis [2]. The mechanism
or mechanisms are important because NO can also dam-
age the heart [3-5], and potently lowers blood pressure
making it impractical to use clinically.
Ischemic preconditioning (a short, non-damaging, period
of ischemia followed by reperfusion) is known to strongly
protect the heart against a subsequent, longer period of
ischemia/reperfusion. NO has been implicated in both
triggering the protection during preconditioning and
mediating the protection during the subsequent ischemia
[1,6,7]. Most studies have indicated that the protective
effect of NO is mediated by stimulation of soluble guan-
ylate cyclase to produce cGMP, which then activates pro-
tein kinase G (PKG) [8], although other studies have
suggested that protection is mediated by NO inhibition of
mitochondrial respiration [9,10], or S-nitrosylation of
proteins such as COX-2 [5]. PKG is thought to protect via
either vasodilation [11], contractility [12], calcium trans-
port [13], or activation of a mitochondrial K+ATP channel
[14].
In contrast to reperfusion-induced necrosis, relatively lit-
tle is known about ischemia-induced apoptosis: the main
subject of this study. It is important to distinguish
between the effects of ischemia and the effects of reper-
fusion on the heart. Necrosis does not occur during
ischemia, but rather during the subsequent reperfusion,
and this has been attributed to either production of reac-
tive oxygen and nitrogen species, pH elevation or calcium
uptake as a result of the return of oxygen, and all of these
can trigger mitochondrial permeability transition. Perme-
ability transition is a large increase in the permeability of
the inner mitochondrial membrane caused by reversible
pore formation, induced by high calcium and/or oxi-
dants, and inhibited by ATP, acid pH and cyclosporine A.
However, we have previously shown that heart ischemia
(in the absence of reperfusion) results in rapid release of
cytochrome c from mitochondria into the cytosol, causing
both activation of caspases (and subsequent nuclear
apoptosis) and inhibition of the mitochondrial respira-
tory chain (which might contribute to necrosis at reper-
fusion) [15]. And we found that all of these ischemia-
induced events are blocked by inhibiting the mitochon-
drial permeability transition pore [15], suggesting that
ischemia induces permeability transition, which triggers
cytochrome c release. The role of apoptosis in ischemic
damage to the heart is still unclear, but inhibition of
apoptosis in a variety of animal models has been shown
to protect the heart from ischemic/reperfusion damage
[16,17], indicating that apoptosis can contribute to this
heart pathology.
It is not known whether NO can protect the heart via
acutely inhibiting ischemia-induced apoptosis, therefore
we sought to determine what effects acute addition of an
NO donor might have on ischemia-induced mitochon-
drial dysfunction, cytochrome c release and caspase acti-
vation, and by what mechanism.
Methods
The procedures used in this study were in compliance
with the European Convention for the protection of vertebrate
animals used for experimental and other purpose.
Hearts from 2–4 months old male Wistar rats were used in
all experiments. Animals were divided into three main
groups: control, ischemia and ischemia-reperfusion
groups. The ischemic and ischemic-reperfusion groups
were further divided into several subgroups in which
hearts were pre-treated with DETA/NO in the presence/
absence of various inhibibitors. All hearts were perfused
on a Langendorff perfusion system with Krebs-Henseleit
solution (11 mM glucose, 118 mM NaCl, 25 mM
NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM CaCl2,
1.7 mM MgSO4 and 0.7 mM Na pyruvate, saturated with
95% O2-5% CO2, pH 7.4 at 37°C) at a pressure of 80 cm
H2O. After a 15-minute equilibration period 50 μM
DETA/NO (Alexis) was added to the perfusion buffer and
hearts were perfused for another 3 min with buffer con-
taining DETA/NO. Control hearts were perfused for 20
min (15 min equilibration plus additional 3–5 min) with
buffer only. After the equilibration period (and perfusion
with DETA/NO where appropriate) hearts were subjected
to 30 minutes stop-flow global ischemia. In reperfusion
experiments, hearts were subjected to 30 minutes stop-
flow global ischemia followed by 30 min reperfusion. In
some experiments where inhibitors were used (1 μM KT
5823, the protein kinase G inhibitor from Calbiochem, 25
μM 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one
(ODQ), the guanylyl cyclase inhibitor from Sigma, or 100
μM 5-hydroxy decanoate (5-HD), the mitochondrial
K+ATP channel blocker from Sigma, 0.5 μM Ro 32-0432
and 1 μM Ro 31-8220, the protein kinase C inhibitors
from Calbiochem and Sigma, respectively) they were
added to the perfusion media 5–15 min prior to perfusion
with DETA/NO. Data obtained in each group were com-
pared to control group and ischemic or ischemic/reper-
fusion group, respectively.Page 2 of 12
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was measured in 1 ml of oxygenated perfusion buffer at
37°C using NO sensitive electrode and was found to be
281 ± 55 nM.
KCl-based buffers were used for mitochondrial isolation
in order to get higher yields of mitochondria. Hearts were
cut into small pieces and homogenized with a teflon-glass
homogenizer in the isolation buffer (10 ml/g of tissue)
containing 180 mM KCl, 20 mM Tris HCl, 1 mM EGTA,
pH 7.3 at 4°C temperature. Cytosolic and mitochondrial
fractions were separated by differential centrifugation (5
min × 750 g, 10 min × 6800 g). The post-mitochondrial
supernatant was additionally centrifuged for 30 min at
10000 g and the resulting supernatant (S10) was used for
determination of cytochrome c content in cytosol. Total
cytosolic and mitochondrial protein was measured by a
Biuret method.
Mitochondrial respiration rate and membrane potential
were measured with a Clarke-type oxygen electrode and a
tetraphenylphosphonium-selective electrode as described
in [18]. The composition of mitochondrial incubation
buffer A was 110 mM KCl, 2.24 mM MgCl2, 10 mM Tris
HCl, 5 mM KH2PO4, 4 IU/ml creatine kinase, 50 mM cre-
atine (pH 7.2 at 37°C). 5 mM succinate (plus 1 μM roten-
one) was used as respiratory substrate. Mitochondrial
state 3 respiration rate was achieved by adding 1 mM ATP
in the presence of creatine kinase and creatine, which con-
vert the ATP into ADP. The kinetics of the respiratory
chain was determined as the dependence of the mito-
chondrial respiration rate on the membrane potential,
when the latter was titrated with carboxyatractyloside
(0.4–8 nmol/mg mitochondrial protein). The kinetics of
the proton leak was measured as the rate of mitochondrial
respiration in the presence of excess oligomycin 1 μg/mg
protein (to prevent phosphorylation). This was deter-
mined over a range of different values of membrane
potential by titrating with malonate (0.33–6 mM) – an
inhibitor of the respiratory chain.
Isolated heart mitochondria were preincubated 1–2 min
at room temperature in hypotonic conditions: 1 volume
of mitochondrial suspension (at 20 mg/ml in isolation
buffer) was added to 2 volumes of de-ionized water (so
the final buffer contained 60 mM KCl, 6.7 mM Tris, and
0.3 mM EGTA, pH 7.3). Then 500 μM pyruvate plus 500
μM malate, 100 μM cGMP, 100 μM ATP and 40 IU/ml
PKG Iα (bovine, recombinant; from Calbiochem), phos-
phatase inhibitor cocktail (1:100 dilution; from Sigma)
were added and incubated 15 min at room temperature.
Control mitochondria were preincubated in the same way
only without PKG. Afterwards aliquots containing 0.2–
0.5 mg mitochondrial protein were taken and added to 1
ml of the mitochondrial incubation buffer B (135 mM
KCl, 30 mM Tris, 5 mM KH2PO4, 5 mM nitrilo-triacetic
acid (NTA), 1.5 mM MgCl2, 1 mM pyruvate plus 1 mM
malate, pH 7.2), and mitochondrial respiration, swelling
and calcium accumulation were measured.
Mitochondrial respiration was measured in the incuba-
tion buffer B containing 135 mM KCl, 30 mM Tris, 5 mM
KH2PO4, 5 mM NTA, 1.5 mM MgCl2, 1 mM pyruvate plus
1 mM malate, pH 7.2 as described above. State 3 respira-
tion rate was initiated by adding 1 mM ADP. Mitochon-
drial swelling was assayed in buffer B by measuring a
decrease in absorbance at 540 nm after addition of 250
μM CaCl2. After 15 min incubation mitochondria were
centrifuged at 13000 rpm × 3 min in an Eppendorf centri-
fuge and supernatants were used for spectrophotometric
measurements of cytochrome c as described in [19,20].
Mitochondrial calcium retention capacity was measured
fluorimetrically using Calcium Green-5N (Molecular
Probes, excitation at 506 nm, emission at 535 nm) which
detects extramitochondrial Ca2+. The incubation buffer C
contained 200 mM sucrose, 10 mM Tris-HCl, 1 mM
KH2PO4, 10 μM EGTA, 0.3 mM pyruvate plus 0.3 mM
malate, pH 7.4, 25°C, final volume 3 ml [21]. Calcium
Green concentration in the medium was 100 nM. Calibra-
tion of the signal was achieved by the addition of known
amounts of Ca2+. Experiments were started by the addi-
tion of 0.2 mg/ml mitochondria, then 10 μM CaCl2 pulses
were added approximately every 3 min (after ~90% of
added calcium was taken up by mitochondria) until
opening of permeability transition pore occurred which
was recorded as a large increase in fluorescence due to
release of accumulated Ca2+ from mitochondria.
For measurement of cytochrome c, mitochondria were
solubilized with 1% Triton X-100 (w/v). Sodium hydro-
sulphite-reduced minus hydrogen-peroxide-oxidized
absorption spectra difference was recorded with a Hitachi-
557 spectrophotometer. Cytochrome c+c1 content was
estimated by using the absorption difference at the wave-
length pair 550/535 nm and ε = 14.5 mM-1cm-1 as
described in [20]. The cytochrome c content in cytosolic
fractions was detected using Quantikinine M rat/mouse
Immunoassay ELISA kit (R&D Systems). Cytosolic frac-
tion proteins were dissolved in 0.5% Triton X-100 and
further procedures were performed according to the man-
ufacturer's protocol.
Lactate dehydrogenase (LDH) activity in the coronary
effluent was measured spectrophotometrically [22] by
monitoring the rate of decrease in NADH (at 340 nm) as
pyruvate is converted to lactate. The LDH activity was
measured by addition of effluent to 0.1 M Tris-HCl buffer
(pH 7.5) containing 0.1 mM NADH and 1 mM Na-pyru-
vate. A unit of LDH was defined as the amount of enzymePage 3 of 12
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(IU).
The activity of caspases was measured as described in [15].
Cytosolic fractions were prepared from heart homoge-
nates in sucrose-based medium (250 mM sucrose, 5 mM
HEPES, 2 mM EGTA, 1 mg/ml albumin) by differential
centrifugation: 5 min × 750 g, 10 min × 6800 g, and 30
min × 10000 g. Sucrose-based medium rather than KCl-
based buffer was used to avoid possible inhibition of cas-
pase activity by high potassium salt concentrations. 1 mg/
ml of total cytosolic protein was incubated for 30 min in
buffer containing 10% sucrose, 50 mM HEPES, 1 mM
MgCl2, 1 mM ATP (pH 7.4, 37°C) and 0.1 mM z-DEVD-
p-nitroanilide (Alexis), a caspase-3 substrate. The hydrol-
ysis of caspase substrate was followed spectrophotometri-
cally at 405 nm and was calibrated with p-nitroanilide.
DEVD-cleaving activity was completely suppressed by
0.02 mM DEVD-CHO (Alexis), a reversible inhibitor of
caspase-3.
Data are expressed as means ± S.E. of at least 3 separate
experiments. Statistical comparison between experimen-
tal groups was performed by ANOVA followed by Tukey
or LSD tests. A value of p < 0.05 was considered statisti-
cally significant.
Results
DETA/NO protects mitochondrial functions from ischemic 
damage
We investigated whether a 'pure' NO donor DETA/NO can
protect heart mitochondria from ischemia-induced mito-
chondrial damage and by what mechanism. We have pre-
viously shown that heart ischemia results in an inhibition
of the mitochondrial respiratory chain (largely due to
cytochrome c release) and a stimulation of mitochondrial
proton permeability (largely due to increased free fatty
acids) [18]. So we tested here whether NO could prevent
these changes, by perfusing rat hearts with 50 μM DETA/
NO for 3 min prior to 30 min of stop-flow ischemia. Mito-
chondria were then rapidly isolated from these and
untreated control hearts, and the activities of the respira-
tory chain and proton leak were determined by simultane-
ously measuring mitochondrial respiration and
membrane potential. We found that 30 min ischemia
caused a 39% decrease in the state 3 respiratory rate (369
± 26 nmol O/min/mg protein in control and 224 ± 11
nmol O/min/mg protein in ischemic mitochondria, p <
0.001) and this was prevented when hearts were pre-per-
fused with DETA/NO prior to ischemia (respiratory rate in
ischemic DETA/NO-treated mitochondria was 292 ± 27
nmol O/min/mg protein, p < 0.01 compared to ischemic
mitochondria). Perfusion of the heart with DETA/NO
alone had no effect on the respiration rates of mitochon-
dria isolated from non-ischemic hearts (361 ± 15 and 327
± 28 nmol O/min/mg protein in control and DETA/NO
group) or on the mitochondrial membrane potential (148
± 3 mV and 148 ± 2 mV in state 3 for mitochondria from
control and DETA/NO-perfused hearts, respectively).
Fig. 1A shows the kinetics of the respiratory chain (with
respiratory substrate succinate, in the presence of roten-
one) of mitochondria isolated from control, ischemic and
ischemic + DETA/NO-treated hearts. The kinetics of the
respiratory chain were measured in isolated heart mito-
chondria as the dependence of the mitochondrial respira-
tory rate on membrane potential, when this was decreased
by carboxyatractyloside (0.4–8 nmol/mg mitochondrial
protein). The important point about these measured
kinetics is that they are independent of the mitochondrial
permeability or phosphorylation system, but rather reflect
the overall activity of the respiratory chain and other com-
ponents generating membrane potential in mitochondria
[23]. As can be seen from the decreased respiration rates
of ischemic mitochondria compared to control at any
given membrane potential, ischemia caused a strong inhi-
bition of the respiratory chain (Fig. 1A). However, after
pre-perfusion of hearts with 50 μM DETA/NO, the respi-
ratory chain of ischemia-damaged mitochondria had a
higher activity compared to DETA/NO-untreated ischemic
mitochondria (Fig 1A), i.e. NO partially prevented
ischemic damage to the respiratory chain.
The kinetics of the proton leak were measured (Fig. 1B) as
the dependence of the mitochondrial respiration rate in
the presence of excess oligomycin (1 mg/mg protein used
to inhibit phosphorylation) on membrane potential
when this was decreased by malonate (0.33–6 mM). In
these conditions, the respiration rate is proportional to
the rate of proton leak, and these kinetics reflect the per-
meability of the inner membrane to protons [24]. As can
be seen from Fig. 1B, at each particular value of mem-
brane potential, the respiration rate of ischemic mito-
chondria was at least twice that of control mitochondria.
This indicates that ischemia increases the mitochondrial
proton leak, which we have previously attributed to an
increase in free fatty acids [18]. However, pre-perfusion of
the heart with DETA/NO largely prevented the ischemia-
induced increase of proton leak (Fig 1B).
We additionally studied whether treatment of the heart
with DETA/NO would increase the capacity of subse-
quently isolated mitochondria to retain calcium. This was
assayed by measuring the extramitochondrial Ca2+ con-
centration fluorimetrically with Calcium Green-5N. The
addition of CaCl2 (2.5 μM) resulted in an immediate
increase of extramitochondrial Ca2+ concentration (meas-
ured as an increase in fluorescence), followed by Ca2+
accumulation in the mitochondrial matrix (decrease of
fluorescence), and subsequent additions of CaCl2 werePage 4 of 12
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:70 http://www.jbiomedsci.com/content/16/1/70repeated until the opening of the permeability transition
pore occurred, which was recorded as a large, irreversible
increase in fluorescence. We found that in mitochondria
isolated from non-ischemic DETA/NO-perfused hearts
45% more calcium was necessary to cause permeability
transition compared to control mitochondria (Fig. 2). But
when hearts were perfused with both DETA/NO and the
PKG inhibitor, the Ca2+ retention capacity was signifi-
cantly reduced (relative to mitochondria from hearts per-
fused with DETA/NO alone), and were similar to the
untreated control level (Fig. 2). Mitochondria isolated
from hearts after 30 min ischemia had a much lower
capacity to accumulate Ca2+ compared to control mito-
chondria, however, this capacity was significantly (by 2.5-
fold) increased if the hearts were pre-perfused with DETA/
NO prior to induction of 30 min ischemia. This indicates
that NO treatment of heart increases the capacity of mito-
chondria to accumulate calcium, presumably by activat-
ing PKG which inhibits permeability transition.
Altogether, the data suggest that NO, in a PKG-dependent
manner, protects mitochondrial function from ischemic
damage mainly by preserving the intactness of the mito-
chondrial membranes: preventing the inner membrane
from becoming leaky to protons, and outer membrane
from becoming leaky for cytochrome c.
DETA/NO prevents ischemia-induced cytochrome c 
release, caspase activation and necrosis via PKG
Next we investigated whether DETA/NO could prevent
the ischemia-induced release of cytochrome c from mito-
chondria to cytosol and subsequent caspase activation in
perfused rat hearts. After 30 min of heart ischemia, the
mitochondrial cytochrome c content had decreased by
31% compared to the non-ischemic control (Fig. 3A). 3
min pre-perfusion with 50 μM DETA/NO completely pro-
tected mitochondria from cytochrome c loss: mitochon-
drial cytochrome c content in ischemic hearts treated with
DETA/NO was not different from non-ischemic control
levels. Cytochrome a/a3 remained unchanged in all treat-
ments (data not shown) indicating that the mitochondrial
inner membrane was not damaged and the changes in
cytochrome c spectra were relatively specific for cyto-
chrome c content. Concomitant with the decrease of mito-
chondrial cytochrome c during ischemia, there was an
increase in cytosolic cytochrome c, and this was prevented
when hearts were pre-perfused with DETA/NO (Fig 3B).
Selective PKG inhibitor KT5823 at 1 μM concentration
applied together with DETA/NO before ischemia signifi-
cantly decreased the ability of DETA/NO to prevent cyto-
chrome c loss from mitochondria and its accumulation in
cytosol: mitochondrial cytochrome c level was signifi-
cantly reduced and cytosolic level significantly increased
Perfusion of hearts with DETA/NO partially prevents the ischemia-induced decrease in respiratory chain activity and increase in prot leak of subsequently isolated mitochondriaFigure 1
Perfusion of hearts with DETA/NO partially prevents the ischemia-induced decrease in respiratory chain activ-
ity and increase in proton leak of subsequently isolated mitochondria. (A): kinetics of the respiratory chain activity, 
and (B): kinetics of proton leak. Rat hearts were perfused for 3 min with 50 μM of DETA/NO, then ischemia was induced for 
30 min. Isolated mitochondria were placed in a vessel with incubation buffer A (see Methods) and their oxygen consumption 
and membrane potential were measured simultaneously. 5 mM succinate (plus 1 μM rotenone) was used as respiratory sub-
strate. Kinetics of the respiratory chain was determined as the dependence of the mitochondrial respiration rate on the mem-
brane potential by titrating with carboxyatractyloside (0.4–8.0 nmol/mg mitochondrial protein). The kinetics of the proton leak 
was measured in the presence of excess oligomycin (1 μg/mg protein), mitochondrial respiration and membrane potential were 
titrated with malonate (0.33–6 mM). Means ± standard errors of 5 separate experiments are presented.
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pared to DETA/NO perfused hearts (Fig. 3A and 3B). Sim-
ilarly, ODQ – a selective inhibitor of NO-sensitive
guanylyl cyclase, abolished the protective effect of DETA/
NO against ischemia-induced release of cytochrome c
from mitochondria (Fig. 3A).
Similar results were obtained when the heart was reper-
fused after ischemia (Fig. 4). The amount of mitochon-
drial cytochrome c after 30 min ischemia followed by 30
min reperfusion was by 21% lower compared to the con-
trol (Fig. 4A). Pre-treatment with DETA/NO partially
blocked this ischemia/reperfusion-induced loss, and the
protective effect of DETA/NO was completely eliminated
by PKG inhibitor KT5823 (Fig. 4A). The cytochrome c
content of cytosolic extracts from ischemia/reperfused
hearts increased by 63% compared to control, while in
hearts pre-treated with DETA/NO there was no significant
increase in cytosolic cytochrome c compared to the non-
ischemic control level (Fig. 4B). These data indicate that
NO, acting via PKG, prevents the cytochrome c release
from mitochondria to cytosol induced by both ischemia
and ischemia plus reperfusion.
It has been shown that PKG may open mitochondrial
K+ATP channels (mtKATP) [14,25], which may play a role in
cardioprotection. Therefore we tested whether the effect of
DETA/NO on mitochondrial cytochrome c release might
be related to opening of mtKATP channels. 5-hydroxyde-
canoate (5-HD) blocks the mtKATP channel, and perfusion
of heart with 5-HD has been shown to block NO-induced
protection against ischemia/reperfusion-induced necrosis
[26]. However, we found that 15 min pre-perfusion with
100 μM 5-HD did not alter DETA/NO-induced protection
against ischemia-induced cytochrome c release: mito-
chondrial cytochrome c content in nmol/mg mitochon-
drial protein was 0.43 ± 0.03 in control, 0.30 ± 0.02 in 30
min ischemic, 0.37 ± 0.01 in DETA/NO-pretreated
ischemic, and 0.37 ± 0.01 in DETA/NO- plus 5-HD-pre-
treated ischemic mitochondria (n = 4) suggesting that the
protective effect of DETA/NO is not mediated through
mtKATP channels. Perfusion with DETA/NO, KT5823 or 5-
HD alone had no effect on mitochondrial cytochrome c
content.
Recently it has been reported that protein kinase Cε
(PKCε) may be a downstream target of PKG in mitochon-
dria inhibiting mitochondrial permeability transition
pore [25,27]. To test whether PKC is involved in DETA/
NO-induced protection of heart mitochondria against
ischemia-induced loss of cytochrome c we pre-perfused
the hearts with DETA/NO in the presence of selective
inhibitors of PKC – Ro 32-8220 and Ro 31-0432, and then
subjected the hearts to 30 min ischemia. As summarised
in Fig. 5, both inhibitors of PKC practically eliminated the
protective effect of DETA/NO: the levels of cytochrome c
in mitochondria isolated from ischemic hearts treated
with DETA/NO plus PKC inhibitors were as low as the lev-
els in non-treated ischemic mitochondria and substan-
tially lower than in ischemic mitochondria treated with
DETA/NO only (Fig. 5). This suggests that PKC is involved
in a DETA/NO-activated cascade of events leading to inhi-
bition of cytochrome c release from mitochondria during
ischemia.
Release of cytochrome c from mitochondria to cytosol can
cause caspase activation, and this has previously been
shown to occur in perfused heart after ischemia [15]. In
this work we tested whether pre-ischemic perfusion of
Perfusion of hearts with DETA/NO increases the calcium-r tent capacity of subsequently isolat d mitochondriaFigure 2
Perfusion of hearts with DETA/NO increases the cal-
cium-retention capacity of subsequently isolated 
mitochondria. Rat hearts were perfused with Krebs-
Henseleit solution only (control group) or with 50 μM 
DETA/NO for 3 min (DETA/NO group) or with 1 μM of 
PKG inhibitor KT 5823 for 5 min prior to perfusion with 
DETA/NO (DETA/NO + PKG inhibitor group). 30 min 
ischemia was induced as described in Methods. Isolated mito-
chondria (0.2 mg protein) were added to 3 ml incubation 
buffer C (200 mM sucrose, TrisHCl 10 mM, KH2PO4 1 mM, 
EGTA 10 μM, 0.3 mM pyruvate plus 0.3 mM malate, pH 7.4) 
and mitochondrial Ca2+ accumulation was measured fluori-
metrically using Calcium Green-5N (excitation at 506 nm, 
emission at 535 nm) as described in Methods. Ca2+ retention 
capacity (amount required to be accumulated before large 
increase in fluorescence was observed due to opening of per-
meability transition pore) of control mitochondria was 124.6 
± 6.5 nmol/mg protein and was equated to 100%. * – statisti-
cally significant effect (p < 0.05, Tukey test) if compared to 
control, # – statistically significant effect of PKG inhibitor (p 
< 0.05, LSD test) if compared to DETA/NO group, ^ – statis-
tically significant effect of DETA/NO if compared to ischemic 
group (p < 0.05, Tukey test). Means ± standard errors of 3–5 
separate experiments are presented.
0
50
100
150
200
Ca
2+
ac
cu
m
u
la
tio
n,
 %
Ca2+ ACCUMULATION
*
#
*
* ^
30 min ISCHEMIA
+DETA/NO
+ DETA/NOCONTROL
+PKG
InhibitorPage 6 of 12
(page number not for citation purposes)
Journal of Biomedical Science 2009, 16:70 http://www.jbiomedsci.com/content/16/1/70
Page 7 of 12
(page number not for citation purposes)
Perfusion of hearts with DETA/NO prevents ischemia-induced release of cytochrome c from mitochondriaFigure 3
Perfusion of hearts with DETA/NO prevents ischemia-induced release of cytochrome c from mitochondria. (A) 
– mitochondrial cytochrome c, (B) – cytosolic cytochrome c. Content of cytochrome c in isolated mitochondria was measured 
spectrophotometrically from the characteristic spectra as described in Methods and was expressed as nmol/mg of mitochon-
drial protein. Cytosolic cytochrome c content was measured using ELISA kit and was expressed in ng/μg of cytosolic protein. * 
– Statistically significant effect of ischemia if compared to control (p < 0.01, Tukey test); # – statistically significant effect of 
DETA/NO if compared to ischemia (p < 0.01, Tukey test); ^ – statistically significant effect of KT 5823 (p < 0.05, LSD test) or 
ODQ (p < 0.01, Tukey test) if compared to ischemia + DETA/NO group. Means ± standard errors of 4–9 separate experi-
ments are presented.
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Journal of Biomedical Science 2009, 16:70 http://www.jbiomedsci.com/content/16/1/70hearts with DETA/NO would have any effect on caspase
activation in ischemic or ischemic and reperfused hearts.
As can be seen in Fig. 6A, 30 min ischemia induced a 5-
fold increase in caspase activity compared to the (non-
ischemic) control, and in the presence of DETA/NO, the
ischemia-induced activation of caspases was significantly
reduced (by 54%). The protective effect of DETA/NO was
eliminated when the hearts were pre-perfused with PKG
inhibitor KT2358: the level of ischemia-induced caspase
activation in this group (KT2358 and DETA/NO treat-
ment before ischemia) was as high as in ischemic group
(Fig. 6A). In the ischemia/reperfused hearts, the caspase
activation and its blockage by DETA/NO were very similar
to ischemia alone (Fig 6A). These data indicate that NO
protects the heart from ischemia-induced apoptosis via
PKG activation.
We also tested the effect of DETA/NO on the level of
ischemia/reperfusion-induced necrosis by monitoring
lactate dehydrogenase (LDH) activity in the perfusate.
After 30 min ischemia plus 30 min reperfusion, LDH
activity in the perfusate markedly increased (Fig. 6B), and
pre-perfusion with DETA/NO reduced the LDH activity in
the perfusate back to the control level, indicating that cells
were completely rescued from ischemia/reperfusion-
induced necrosis. KT5823 applied together with DETA/
NO restored necrosis back to a level similar to that
induced by ischemia/reperfusion without DETA/NO,
indicating that PKG mediates the cardioprotective action
of DETA/NO.
The effects of PKG on the functional activity of isolated 
mitochondria
To investigate in more detail which mitochondrial proc-
esses can be influenced by activated PKG we studied the
direct effects of PKG on the functions of isolated mito-
chondria. Isolated heart mitochondria were preincubated
in hypotonic conditions for 1–2 min and then 15 min
with/without added PKG (plus cGMP). This mildly hypo-
tonic preincubation had no significant effect on mito-
chondrial respiration compared to isotonic conditions,
but these hypotonic conditions were needed to reveal a
stable effect of PKG on mitochondrial functions. PKG
added to isolated mitochondria slightly reduced respira-
tion rate in state 3 but had no effect in state 2 (Fig. 7A).
However, this inhibition did not reduce the capacity of
these mitochondria to accumulate added calcium. This
was assayed by measuring the extramitochondrial Ca2+
concentration fluorimetrically with Calcium Green-5N as
described above (in Fig. 2). After hypotonic pre-incuba-
tion with/without PKG mitochondria were transferred to
the buffer C and pulses of CaCl2 were added until the
opening of the permeability transition pore occurred,
which was recorded as a large, irreversible increase in flu-
orescence. The control mitochondria were able to accu-
mulate 111 ± 5 nmol/mg protein of calcium, however the
PKG-treated mitochondria had a higher calcium retention
capacity: 152 ± 3 nmol/mg protein (Fig. 7B). Inhibition of
PKG with DT-3 returned the calcium retention capacity
back to almost the control level (Fig. 7B). As expected, the
presence of cyclosporine A (CsA) to inhibit permeability
transition resulted in a higher calcium retention capacity
(175 ± 1 nmol/mg protein).
Next we investigated whether PKG could block mitochon-
drial swelling triggered by high concentrations of Ca2+,
which is known to be mediated by permeability transi-
tion. As can be seen in Fig. 7C, high-amplitude swelling of
isolated mitochondria was induced by 250 μM CaCl2,
while pre-treatment with PKG significantly blocked this
swelling.
The swelling of mitochondria was accompanied by the
release of cytochrome c from mitochondria to incubation
medium (Fig. 7D). In these experiments, the isolated
mitochondria were preincubated for 15 min in conditions
as described in Fig. 7C, then mitochondria were removed
Perfusion of the hearts with PKC inhibitors abolish the pro-tective effect of DETA/NO against ischemia-induced loss f cytochrome c from mitochondriaFigure 5
Perfusion of the hearts with PKC inhibitors abolish 
the protective effect of DETA/NO against ischemia-
induced loss of cytochrome c from mitochondria. 
Hearts were perfused 15 min with 0.5 μM Ro 32-0432 and 1 
μM Ro 31-8220 followed by 3 min perfusion with 50 μM 
DETA/NO. Then hearts were subjected to 30 min stop-flow 
ischemia. Mitochondrial content of cytochrome c was meas-
ured as described in Methods. * – Statistically significant 
effect of ischemia if compared to control (p < 0.01, Tukey 
test); # – statistically significant effect of DETA/NO if com-
pared to ischemia (p < 0.01, Tukey test); ^ – statistically sig-
nificant effect of PKC inhibitors if compared to DETA/NO 
group (p < 0.05, Tukey test). Means ± standard errors of 4 
separate experiments are presented.
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Journal of Biomedical Science 2009, 16:70 http://www.jbiomedsci.com/content/16/1/70by centrifugation and supernatants were used for spectro-
photometric measurements of cytochrome c. There was
no detectable loss of cytochrome c from mitochondria
when they were incubated without Ca2+. After incubation
of mitochondria with 250 μM CaCl2, there was a substan-
tial increase in the cytochrome c level in supernatants
compared to calcium-free control. This calcium-induced
cytochrome c release was substantially reduced by the
addition of PKG (Fig 7D). These results suggest that PKG
increases the resistance of isolated mitochondria to the
deleterious effects of high calcium: the swelling and
release of cytochrome c due to opening of the permeabil-
ity transition pore were substantially reduced by PKG.
Discussion
We have previously shown that 30 min of heart ischemia
causes cytochrome c release from the mitochondria to the
cytosol, and this causes an inhibition of respiratory chain
function, which can be reversed simply by adding back
exogenous cytochrome c [15]. Here we show that a pure
NO donor (DETA/NO) can reduce these changes, proba-
bly via a PKG-mediated blockage of mitochondrial per-
meability transition and subsequent cytochrome c release.
Ischemia-induced cytochrome c release is important
because: (a) it stimulates caspase activation in the cyto-
plasm, and (b) it may contribute to reperfusion-induced
necrosis or contractile dysfunction, either because it pre-
vents ATP production or because it stimulates reactive
oxygen species production from the respiratory chain. We
find here, consistent with [14,28], that DETA/NO does
indeed protect against reperfusion-induced necrosis via a
PKG-dependent mechanism. We have previously shown
that addition of cytochrome c to heart cytosol (in the pres-
ence of dATP) is sufficient to trigger caspase activation,
and blocking cytochrome c release blocks ischemia-
induced caspase activation and nuclear apoptosis [15,29].
We show here that pre-perfusion of hearts with DETA/NO
blocks the ischemia-induced cytochrome c release and
caspase activation. It is still not entirely clear how
ischemia-induced caspase activation contributes to heart
pathology, but caspase inhibition has been shown to pro-
tect the heart in animal models of ischemia/reperfusion
[16,17].
Ischemia substantially increased the mitochondrial pro-
ton permeability and pre-perfusion with DETA/NO pre-
vented this. We have previously attributed this increased
proton permeability to the measured ischemia-induced
increase in free fatty acids within the mitochondria, as the
permeability increase is reversed simply by incubating the
mitochondria with albumin [18]. It is possible that NO
blocks the ischemia-induced increase in free fatty acids, as
Perfusion of the hearts with DETA/NO blocks caspase activation and necrosis induced by ischemia and ischemia/reperfusionFigure 6
Perfusion of the hearts with DETA/NO blocks caspase activation and necrosis induced by ischemia and 
ischemia/reperfusion. (A) – caspase activity, (B) – lactate dehydrogenase activity in perfusate. Rat hearts were perfused for 
3 min with 50 μM DETA/NO, then hearts were subjected to 30 min ischemia only or to 30 min ischemia plus 30 min reper-
fusion. Where indicated (KT), hearts were perfused with 1 μM KT5823. Coronary effluents during reperfusion were collected 
for determination of LDH activity. Cytosolic fractions were separated by differential centrifugation and were used for determi-
nation of caspase activity spectrophotometrically using z-DEVD-p-nitroanilide, a caspase-3-substrate. * – Statistically significant 
effect of ischemia (I) or I/R (p < 0.01, Tukey test) if compared to control; # – statistically significant effect of DETA/NO (p < 
0.05, Tukey test) if compared to I or I/R respectively. ^ – statistically significant effect of KT5823 (p < 0.05, LSD test) if com-
pared to I/R + DETA/NO group. Means ± standard errors of 4–9 separate experiments are presented.
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Journal of Biomedical Science 2009, 16:70 http://www.jbiomedsci.com/content/16/1/70it has been shown that cGMP-stimulated PKG can phos-
phorylate and inhibit cytosolic phospholipase A2 [30],
which is a likely source of the ischemia-induced increase
in free fatty acids. And the free fatty acids may both
increase proton permeability and stimulate permeability
transition. Alternatively, it may be that mitochondrial per-
meability transition contributes to the proton permeabil-
ity directly or indirectly.
Incubation of isolated heart mitochondria with activated
PKG blocked calcium-induced mitochondrial permeabil-
ity transition and cytochrome c release. We used a mildly
hypotonic medium to obtain these results, because
although we could also see protection by PKG in an isot-
onic medium with some preparations of mitochondria,
the results varied from day to day, whereas there was con-
sistent protection by PKG using a hypotonic medium.
This medium was only mildly hypotonic and had little
The effects of purified PKG on the functional activities of isolated heart mitochondriaFigure 7
The effects of purified PKG on the functional activities of isolated heart mitochondria. (A) – mitochondrial state 2 
and state 3 respiration rates, (B) – mitochondrial Ca2+ accumulation, (C) – mitochondrial swelling, (D) – release of cytochrome 
c from mitochondria. Isolated heart mitochondria were preincubated in hypotonic conditions with 40 U/ml PKG Iα as 
described in Methods. Then mitochondria (0.2–0.5 mg) were added to 1 ml incubation buffer B (plus 1 mM pyruvate and 1 mM 
malate as respiration substrates) and mitochondrial respiration and swelling were measured. Mitochondrial swelling was 
assayed by measuring a decrease in absorbance at 540 nm after addition of 250 μM CaCl2. After 15 min incubation mitochon-
dria were removed by centrifugation, the supernatants were used for spectrophotometric measurements of released of cyto-
chrome c. Mitochondrial calcium accumulation was measured in buffer C fluorimetrically using 100 nM Calcium Green-5N 
(excitation at 506 nm, emission at 531 nm) as described in Methods. DT-3 – protein kinase G Iα inhibitor (from Calbiochem). 
* – statistically significant effect of PKG (or Ca2+) (p < 0.05, Tukey test) if compared to control, # – statistically significant effect 
of PKG inhibitor DT-3 (p < 0.05, Tukey test) if compared to mitochondria + PKG group, ^ – statistically significant effect of 
PKG (p < 0.05, Tukey test) if compared to mitochondria plus Ca2+. Means ± standard errors of 7 separate experiments are 
presented.
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Journal of Biomedical Science 2009, 16:70 http://www.jbiomedsci.com/content/16/1/70effect on the state 3 or state 2 respiratory rate, indicating
that inner and outer mitochondrial membranes were not
ruptured. However, we can not rule out that there was
some mild or transient permeabilisation of the outer
membrane allowing PKG to access intermembrane target
proteins that mediated the protection. Alternatively the
hypotonic treatment may have been required to form con-
tact sites between the inner and outer membrane that
allow changes at the outer membrane to be conveyed to
the inner membrane [31]. In this hypotonic medium, acti-
vated PKG blocked calcium-induced permeability transi-
tion, as measured by swelling and calcium retention. This
suggests that PKG phosphorylated some mitochondrial
component that controls permeability transition.
It has previously been shown that activated PKG can block
permeability transition in isolated brain [32], heart [25]
and liver mitochondria [33], although the mechanism of
the blockage remains unclear. In heart a complex pathway
has been invoked including PKG activating PKCε1, activat-
ing mtKATP, increasing matrix pH, increasing H2O2, acti-
vating PKCε2, and inhibiting permeability transition [25].
However, we found that a mtKATP inhibitor did not pre-
vent NO inhibiting the ischemia-induced cytochrome c
release. It is possible that NO via PKG reduces the sensitiv-
ity of mtKATP to 5-HD [14], such that mtKATP is not inhib-
ited by 100 μM 5-HD in the presence of NO. Alternatively,
mtKATP is not involved in NO protection against apoptosis
(rather than necrosis). This protection may involve NO
activation of sGC to produce cGMP, which activates PKG,
which somehow activates mitochondrial PKC to inhibit
permeability transition, which normally mediates
ischemia-induced cytochrome c release. This would be
consistent with a recent report by Costa et al. [27] show-
ing that exogenous H2O2 or NO inhibit MPTP opening
independently of mtKATP activity via activation of mito-
chondrial PKCε2.
Conclusion
Overall our results indicate that NO can acutely block
ischemia-induced caspase activation, mitochondrial dam-
age and cell death in the heart via PKG, and this may be
mediated by PKG inhibition of mitochondrial permeabil-
ity transition and related loss of cytochrome c from mito-
chondria.
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